Aurobindo Pharma Limited — Important, 23-11-2024: Updates

Aurobindo Pharma USA Inc., a wholly-owned subsidiary, has entered into a collaboration and license agreement with a global pharmaceutical major for the development and commercialization of products in the respiratory therapeutic area. Under this agreement, an upfront payment of USD 25 million will be made on the effective date, with both parties sharing subsequent developmental costs, capped at USD 90 million for Aurobindo. The collaboration is set for an initial development period of three to five years, during which both parties will co-exclusively commercialize the products. The manufacturing will occur at the partner's facility, and Aurobindo retains an option for future technology transfer. This agreement presents a significant opportunity for Aurobindo to enhance its product portfolio while sharing development risks and costs, signaling a positive outlook for shareholders.